An electrolyte including: a lithium salt; a non-aqueous solvent; a compound represented by Formula 1; and a compound represented by Formula 2 ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.11, and R.sub.12 in Formulae 1 and 2 are as described in the detailed description.

An electrolyte including: a lithium salt; a non-aqueous solvent; a compound represented by Formula 1; and a compound represented by Formula 2 ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.11, and R.sub.12 in Formulae 1 and 2 are as described in the detailed description.

Phosphatidylalkanol homologues having isotopically labelled moieties, methods for preparation of isotopically labelled phosphatidylalkanol homologues and uses of isotopically labelled phosphatidylalkanol homologues.

This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Li.sub.x1Co.sub.y1M.sub.1-y1O.sub.2-z1Q.sub.z1, where 0.5≤x1≤1.2, 0.8≤y1<1.0, 0≤z1≤0.1, M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolyte contains an additive A, an additive B, and an additive C. The additive A is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The additive B is a silyl phosphite compound or a silyl phosphate compound or a mixture thereof. The additive C is a halogen substituted cyclic carbonate compound.

Provided herein are compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.a, R.sup.b, and R.sup.c are as defined herein. Also provided are pharmaceutical compositions comprising compounds of structure (I), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and methods for use of compounds of structure (I), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK).

##STR00001##

An organometallic adduct compound and a method of manufacturing an integrated circuit (IC) device, the organometallic adduct compound being represented by General formula (I):

##STR00001## in General formula (I), R.sup.1, R.sup.2, and R.sup.3 are each independently a C1 to C5 alkyl group, at least one of R.sup.1, R.sup.2, and R.sup.3 being a C1 to C5 alkyl group in which at least one hydrogen atom is substituted with a fluorine atom, M is a niobium atom, a tantalum atom, or a vanadium atom, X is a halogen atom, m is an integer of 3 to 5, and n is 1 or 2.

Dihydrogen metaphosphate can be synthesized via protonation, and can react with a dehydrating agent to afford tetrametaphosphate anhydride. A monohydrogen tetrametaphosphate organic ester can be derived from the anhydride. A metal tetrametaphosphate complex can be prepared using a metal salt and a dihydrogen tetrametaphosphate.

This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Li.sub.x1Co.sub.y1M.sub.1-y1O.sub.2-z1Q.sub.z1, where 0.5x11.2, 0.8y11.0, 0z10.1, M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolyte contains an additive A, an additive B, and an additive C. The additive A is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The additive B is a silyl phosphite compound or a silyl phosphate compound or a mixture thereof. The additive C is a halogen substituted cyclic carbonate compound.

Phosphonate based lithium complexes of formula (I) and their use in electrolyte compositions for electrochemical cells. ##STR00001##

The present invention relates to a process for preparing a mixture M1 of enol phosphate isomers devoid of (E,E) isomer and comprising at least 98% of (E,Z) isomer, at least 0.1% of (Z,Z) isomer and at least 0.1% of (Z,E) isomer, comprising bringing a mixture of isomers of said enol phosphate comprising a detectable amount of (E,E) isomer into contact with a hydrolysable dienophile in an organic solvent, followed by base hydrolysis of the medium obtained and elimination of the adduct formed, in order to obtain the mixture M1 devoid of (E,E) isomer.